\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes ERC ERCThe report is based on data retrieved from 6,671 ERC-funded projects from all scientific domains, including all projects funded from 2007 until 2014 (7th Framework Programme - FP7) and part of Horizon 2020 - H2020). The study attempted to answer the question how and to what extent the discoveries described by ERC grantees in scientific publications inspired new technologies presented in patent applications, which were filed by firms and institutions all over the world. A summary of the findings can be found in the executive summary of main findings in the report (p.4-6) and this ERC press release.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
